journal article·2014-02

Eradication of superficial fungal infections by conventional and novel approaches: a comprehensive review

Lalit Kumar, Shivani Verma, Ankur Bhardwaj, Shubha Vaidya, Bhuvaneshwar Vaidya

Publisher page

Abstract

During the last two decades, the occurrence of fungal infections either superficial or systemic has been increasing. Moreover, fungal infections become more difficult to treat when they show coupling with immunogenic diseases like AIDS. Superficial fungal infections are associated with skin, nail and eye and are less prominent to systemic infection. However, it may be dangerous if not treated properly. It is usually observed that conventional formulations including cream, powder, gels etc. are used to treat skin fungal infections even for the deep seated fungal infections. However, these formulations show various side-effects on the application site like burning, redness and swelling. Further, due to the immediate release of drug from these formulations they can stimulate the immune system of body generating high impact allergic reactions. Deep seated fungal infections like invasive aspergillosis and invasive candidiasis may be more difficult to treat because the drug released from conventional topical formulation can not reach at the target site due to the low penetration capacity. Similarly, in case of fungal infection of nail and eye, conventional formulations show problem of less bioavailability. Thus, to overcome the drawbacks of conventional therapy a lot of research works have been carried out to develop novel formulations of antifungal drugs to deliver them superficially. Novel formulations explored for the skin delivery of antifungal drugs include liposomes, niosomes, ethosomes, microemulsions, nanoparticles, microspheres and micelles. These formulations show extended or sustained release of drug, minimizing the side effect on application site, enhancing bioavailability and reducing the dosing frequency. Further, these formulations also show penetration into the deep skin to treat invasive fungal infections. Novel formulations explored in treatment of fungal infections of eye are liposomes and nanoparticles and whether for nail fungal infections microemulsions are the choice. In present article, we have discussed about conventional treatment of superficial fungal infection and their comparison with the novel drug delivery systems.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nail Diseases and Treatments · Advancements in Transdermal Drug Delivery · Dermatology and Skin Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Adams BB · J Am Acad Dermatol · 2002 · 47 · 28610.1067/mjd.2002.120603 ↗
2. Agarwal K · N Engl J Med · 1999 · 340 · 129210.1056/NEJM199904223401617 ↗
3. Agarwal R · Pharm Tech · 2002 · 1
4. Aggarwal N · Int J Pharm · 2012 · 437 · 27710.1016/j.ijpharm.2012.08.015 ↗
5. Alagusundaram M · Int J Chem Tech Res · 2009 · 1 · 526
6. Albertini B · Eur J Pharm Sci · 2009 · 36 · 59110.1016/j.ejps.2008.12.009 ↗
7. Amichai B · Int J Dermatol · 1998 · 37 · 41010.1046/j.1365-4362.1998.00496.x ↗
8. Arikan S · Curr Pharm Res · 2001 · 7 · 39310.2174/1381612013398031 ↗
9. Arora R · Asi J Pharm · 2007 · 1 · 29
10. Ataei S · J Pharm Sci · 2011 · 1 · 50
11. Babel DE · J Am Acad Dermatol · 1989 · 21 · 120910.1016/S0190-9622(89)70331-5 ↗
12. Bachhav YG · J Control Rel · 2011 · 153 · 12610.1016/j.jconrel.2011.03.003 ↗
13. Barot BS · AAPS Pharm Sci Tech · 2011
14. 10.1016/S1359-6446(01)01938-910.1016/S1359-6446(01)01938-9 ↗
15. Bhalaria MK · Ind J Exp Bio · 2009 · 47 · 368
16. Bhalekar MR · AAPS Pharm Sci Tech · 2009 · 10 · 28910.1208/s12249-009-9199-0 ↗
17. Bhatta RS · Int J Pharm · 2012 · 432 · 10510.1016/j.ijpharm.2012.04.060 ↗
18. Blank IH · J Invest Dermatol · 1984 · 82 · 18310.1111/1523-1747.ep12259835 ↗
19. Brodell R · Postgrad Med · 2000 · 107 · 4110.3810/pgm.2000.01.858 ↗
20. 10.1097/01.ico.0000126435.25751.2010.1097/01.ico.0000126435.25751.20 ↗
21. Chudasama A · J Adv Pharm Tech Res · 2011 · 2 · 3010.4103/2231-4040.79802 ↗
22. Del RJ · Curr Infect Dis Rep · 2000 · 2 · 43810.1007/s11908-000-0074-0 ↗
23. Derle DV · Ind J Pharm Sci · 1975 · 68 · 62210.4103/0250-474X.29630 ↗
24. Devi M · Int J Rec Adv Pharm Res · 2011 · 4 · 37
25. Dharma SK · Acta Ophthalmol (Copenh) · 1986 · 64 · 29810.1111/j.1755-3768.1986.tb06923.x ↗
26. Durden F · Semin Cutan Mecl Surg · 1997 · 16 · 20010.1016/S1085-5629(97)80043-0 ↗
27. Elewski B · Arch Dermatol · 1999 · 133 · 117210.1001/archderm.1997.03890450124022 ↗
28. Elewski B · J Am Acad Dermatol · 2000 · 42 · 110.1016/S0190-9622(00)90001-X ↗
29. El-Hadidy GN · Drug Dev Ind Pharm · 2011 · 1
30. Evans E · BMJ · 1999 · 318 · 103110.1136/bmj.318.7190.1031 ↗
31. 10.1046/j.1365-2133.149.s65.4.x10.1046/j.1365-2133.149.s65.4.x ↗
32. Faraday M · Phil Trans Roy Soc Lond · 1857 · 147 · 14510.1098/rstl.1857.0011 ↗
33. Fawzia SH · Acta Ophthalmol · 2010 · 88 · 90110.1111/j.1755-3768.2009.01584.x ↗
34. Firthouse PUM · Int J Pharm Tech Res · 2011 · 3 · 1019
35. Fleece D · Pediatrics · 2004 · 114 · 131210.1542/peds.2004-0428 ↗
36. 10.1016/S0161-6420(91)32227-910.1016/S0161-6420(91)32227-9 ↗
37. Ghannoum M · J Clin Microbiol · 2006 · 44 · 257910.1128/JCM.00818-06 ↗
38. Goldstein A · Geriatrics · 2000 · 55 · 40
39. 10.3109/0265204980900684410.3109/02652049809006844 ↗
40. 10.1016/S0733-8635(03)00032-910.1016/S0733-8635(03)00032-9 ↗
41. Gupta AK · Am J Clin Dermatol · 2004 · 5 · 22510.2165/00128071-200405040-00003 ↗
42. Gupta AK · J Am Acad Dermatol · 2000 · 43 · 7010.1067/mjd.2000.109071 ↗
43. Gupta M · J Lip Res · 2010 · 20 · 34110.3109/08982101003596125 ↗
44. Gupta M · Pharm Dev Tech · 2011
45. 10.1016/j.chemphyslip.2012.01.00610.1016/j.chemphyslip.2012.01.006 ↗
46. 10.1001/archderm.1997.0389046002900410.1001/archderm.1997.03890460029004 ↗
47. Hart R · BMJ · 1999 · 319 · 7910.1136/bmj.319.7202.79 ↗
48. Hashem FM · AAPS Pharm Sci Tech · 2011 · 12 · 87910.1208/s12249-011-9653-7 ↗
49. Hu C · Int J Pharm · 1999 · 185 · 2310.1016/S0378-5173(99)00122-2 ↗
50. 10.3109/10717544.2010.48325210.3109/10717544.2010.483252 ↗
51. Jaya RK · J Pharm Res · 2012 · 5 · 2385
52. Jaydeep DY · J Pharm Res · 2011 · 4 · 632
53. 10.7326/0003-4819-137-2-200207160-0000810.7326/0003-4819-137-2-200207160-00008 ↗
54. Jones MC · Eur J Pharm Biopharm · 1999 · 48 · 10110.1016/S0939-6411(99)00039-9 ↗
55. Kassem MAA · Mycoses · 2005 · 49 · 23210.1111/j.1439-0507.2006.01221.x ↗
56. 10.1002/jps.1042010.1002/jps.10420 ↗
57. Katz H · J Am Podiatr Med Assoc · 1997 · 87 · 57110.7547/87507315-87-12-571 ↗
58. Kaur IP · Int J Pharm · 2004 · 269 · 110.1016/j.ijpharm.2003.09.016 ↗
59. 10.1517/17425247.2010.52523010.1517/17425247.2010.525230 ↗
60. Kaur IP · J Ocul Pharmacol Ther · 2008 · 24 · 48110.1089/jop.2008.0031 ↗
61. 10.1016/S0169-409X(00)00124-110.1016/S0169-409X(00)00124-1 ↗
62. Korting HC · Am J Clin Dermatol · 2007 · 8 · 35710.2165/00128071-200708060-00005 ↗
63. Kotwani RN · Ind Pediatr · 2003 · 40 · 545
64. Kreilgaard M · Bull Technique Gattefosse · 2002 · 95 · 79
65. Kumar P, Mittal KL. 1998. Hand Book of Microemulsions: Science and Technology. New York, NY: Marcel Dekker, pp. 20–22.
66. Kuvandik G · BMC Infect Dis · 2007 · 7 · 10210.1186/1471-2334-7-102 ↗
67. Laithy HM · AAPS Pharm Sci Tech · 2002 · 3 · 3510.1208/pt030210 ↗
68. Lazaros GA · J Hepatol · 1996 · 24 · 75310.1016/S0168-8278(96)80273-X ↗
69. Le BC · Prog Retin Eye Res · 1998 · 17 · 3310.1016/S1350-9462(97)00002-5 ↗
70. 10.4333/KPS.2010.40.5.30510.4333/KPS.2010.40.5.305 ↗
71. Li L · J Dent Res · 2007 · 86 · 20410.1177/154405910708600304 ↗
72. Maestrelli F · J Lip Res · 2009 · 1
73. Maheshwari RGS · Saudi Pharm J · 2012
74. Maiti S · AAPS Pharm Sci Tech · 2009 · 10 · 70310.1208/s12249-009-9257-7 ↗
75. Malhotra M · Ind Drugs · 1994 · 31 · 81
76. 10.1517/14656566.2.11.184910.1517/14656566.2.11.1849 ↗
77. McClellan K · Drugs · 1999 · 58 · 17910.2165/00003495-199958010-00018 ↗
78. Mitkari BV · Ind J Pharm Edu Res · 2010 · 44 · 324
79. 10.4314/tipr.v5i1.1463410.4314/tipr.v5i1.14634 ↗
80. Moossavi M · Dermatol Clin · 2001 · 19 · 3510.1016/S0733-8635(05)70228-X ↗
81. Muller RH · Adv Drug Deliv Rev · 2002 · 54 · S13110.1016/S0169-409X(02)00118-7 ↗
82. Muller RH · Eur J Pharm Biopharm · 2000 · 50 · 16110.1016/S0939-6411(00)00087-4 ↗
83. Müller RH · Pharm Tech Europe · 2005 · 17 · 45
84. Müller RH · Int J Pharm · 2002 · 242 · 12110.1016/S0378-5173(02)00180-1 ↗
85. Nagarsenker MS · Int J Pharm · 1999 · 190 · 6310.1016/S0378-5173(99)00265-3 ↗
86. Nair R · Der Pharm Let · 2010 · 2 · 99
87. 10.1081/DDC-5431510.1081/DDC-54315 ↗
88. Norbert M · Expert Opin Biol Ther · 2001 · 1 · 110.1517/14712598.1.1.1 ↗
89. Okada H · Crit Rev Ther Drug Carrier Syst · 1995 · 12 · 110.1615/CritRevTherDrugCarrierSyst.v12.i1.10 ↗
90. Ola HE · Saudi Pharm J · 2010 · 18 · 21710.1016/j.jsps.2010.07.003 ↗
91. Paolicellia P · J Chem Pharm Res · 2011 · 3 · 410
92. Patel MR · Acta Pharm Sci · 2010 · 52 · 65
93. Patel PR · Int J Drug Del Tech · 2009 · 1 · 42
94. 10.1080/0193269970894374010.1080/01932699708943740 ↗
95. Perveze Z · Liver Transpl · 2007 · 13 · 16210.1002/lt.21034 ↗
96. Pfaller MA · J Clin Microbiol · 2004 · 42 · 314210.1128/JCM.42.7.3142-3146.2004 ↗
97. Piemi MPY · J Control Rel · 1999 · 58 · 17710.1016/S0168-3659(98)00156-4 ↗
98. 10.1021/js980259410.1021/js9802594 ↗
99. Rivera PA · J Microencapsul · 2004 · 21 · 20310.1080/02652040310001637811 ↗
100. 10.2165/00137696-200604040-0000610.2165/00137696-200604040-00006 ↗